Clinical Trial: NCT04224337
Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Seoul National University Hospital |
| Information Provided By: | Seoul National University Hospital |
| Last Update Posted: | 2025-12-31 |
Study Overview
Brief Summary
To evaluate the efficacy and safety of durvalumab in combination with doxorubicin and ifosfamide in patients with PSC.
Official Title
Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma
Conditions
Carcinoma, Non-Small-Cell Lung
Intervention / Treatment
- Drug: Durvalumab + doxorubicin + ifosfamide
Other Study ID Numbers
- PSC2
Start Date (Actual)
2020-06-11
Primary Completion Date (Actual)
2023-08-14
Study Completion Date (Actual)
2025-05-07
Enrollment (Actual)
16
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Seoul National University Hospital |
| Information Provided By: | Seoul National University Hospital |
| Last Update Posted: | 2025-12-31 |
Study Overview
Brief Summary
To evaluate the efficacy and safety of durvalumab in combination with doxorubicin and ifosfamide in patients with PSC.
Official Title
Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma
Conditions
Carcinoma, Non-Small-Cell Lung
Intervention / Treatment
- Drug: Durvalumab + doxorubicin + ifosfamide
Other Study ID Numbers
- PSC2
Start Date (Actual)
2020-06-11
Primary Completion Date (Actual)
2023-08-14
Study Completion Date (Actual)
2025-05-07
Enrollment (Actual)
16
Study Type
Interventional
Phase
Phase 2